SQ2201 / Shasqi - LARVOL DELTA

Shasqi Publishes Data on Systemic Antigen Targeting Approach, Using Click Chemistry to Activate MMAE in Tumors (PRNewswire) - "Shasqi, Inc...today announced the expansion of its Click Activated Protodrugs Against Cancer (CAPAC ®) platform with a pivotal manuscript describing the preclinical development of SQ2201, a novel cancer therapy....SQ2201 showed potent anti-tumor effects in mice that surpassed those seen with a biosimilar of disitamab vedotin, a conventional ADC which targets the same antigen and delivers the same payload."

Preclinical • Oncology • Solid Tumor